Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

November 26, 2015 10:53 PM ET


Company Overview of Rhythm Pharmaceuticals, Inc.

Company Overview

Rhythm Pharmaceuticals, Inc. operates as a biopharmaceutical company. The company develops peptide therapeutics for the treatment of gastrointestinal (GI) diseases; and obesity, including obesity caused by genetic deficiencies in the MC4 pathway. Its portfolio includes relamorelin (RM-131), a ghrelin peptide agonist for the treatment of diabetic gastroparesis, a GI complication of diabetes and other GI functional disorders; and RM-493, a melanocortin-4 (MC4) receptor agonist for the treatment of obesity and obesity caused by genetic deficiencies in the MC4 pathway. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is based in Boston, Massachusetts.

855 Boylston Street

11th Floor

Boston, MA 02116

United States

Founded in 2008





Key Executives for Rhythm Pharmaceuticals, Inc.

Chairman and Chief Executive Officer
Age: 61
Founder and President
Age: 56
Founder and Chief Development Officer
Age: 65
Chief Scientific Officer
Age: 60
Compensation as of Fiscal Year 2015.

Rhythm Pharmaceuticals, Inc. Key Developments

Rhythm Pharmaceuticals, Inc. Presents Positive Data from Phase 1B Study of Setmelanotide for the Treatment of Genetic Obesity

Rhythm Pharmaceuticals, Inc. announced the results from a proof-of-concept, Phase 1b clinical trial assessing the safety and efficacy of setmelanotide (RM-493), the company's novel melanocortin-4 receptor (MC4R) agonist, in obese patients with a heterozygous genetic defect in MC4R. The trial demonstrated that after four weeks of treatment, setmelanotide reduced weight in patients with an MC4R heterozygous deficiency obesity, with good tolerability. The study results were featured in an oral presentation at the ObesityWeek 2015 conference in Los Angeles. Setmelanotide activates MC4R, which is part of the key pathway that can independently regulate energy homeostasis and appetite. The critical role of the MC4 pathway in weight regulation was validated with the discovery that single genetic defects along this pathway result in early onset and severe obesity. An expanding set of severe obesity genetic defects are now identified that involve genes in the pathway that are either upstream of MC4R—specifically, pro-opiomelanocortin (POMC) deficiency obesity, leptin receptor deficiency obesity, and likely Prader-Willi Syndrome (PWS)—or genes that are downstream of MC4R or that affect MC4R itself. In this pilot study, obese (BMI >/= 30kg/m2) patients with a heterozygous MC4R loss-of-function mutation were enrolled in a double-blind, placebo-controlled, randomized, parallel-group study for 4 weeks. Eight patients (six active, two placebo) received placebo or RM-493 at 0.01 mg/kg/day by continuous subcutaneous infusion. Key endpoints were safety, weight loss, waist circumference, and caloric intake. Setmelanotide was well tolerated over 4 weeks, with no serious adverse events or discontinuations. The most common side effects were headache and skin tanning, with the latter believed to be due to off-target activity at the related melanocortin-1 receptor. Setmelanotide demonstrated strong trends for placebo-subtracted weight loss (-2.62 kg; p=0.088); WC (-5.1 cm; p=0.188) and daily caloric intake (-351 kCal/day; p=not significant), without clinically important effects on heart rate or blood pressure.

Rhythm Pharmaceuticals Inc. Presents at BIO International Convention, Jun-25-2014 10:30 AM

Rhythm Pharmaceuticals Inc. Presents at BIO International Convention, Jun-25-2014 10:30 AM. Venue: San Diego Convention Center, San Diego, California, United States.

Similar Private Companies By Industry

Company Name Region
Sitari Pharmaceuticals, Inc. United States
SAFC Carlsbad, Inc. United States
Predict, Inc. United States
PPD Development, LP United States
METAMUNE, iNC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Rhythm Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at